Systematic versus selective heparin use to prevent radial artery occlusion after catheterization
Comparaison d'un Traitement systématique à l'héparine Versus sélectif Pour la prévention de l'Occlusion Radiale EASY-Héparine
This test compares giving heparin to all patients versus only to selected patients to see which approach better prevents radial artery blockage after diagnostic transradial catheterization.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Trial ID | NCT06981624 on ClinicalTrials.gov |
What this trial studies
Adults referred for diagnostic transradial catheterization are randomized to a routine (systematic) heparin strategy or an elective/selective heparin strategy, with hemostasis managed using a dual-artery compression system. The main outcome is occurrence of radial artery occlusion after the procedure. Patients who cannot consent or cannot receive required antiplatelet or anticoagulant medications are excluded. The trial is conducted at a single tertiary cardiac center with follow-up to document artery patency and immediate postprocedural complications.
Who should consider this trial
Good fit: Adults referred for diagnostic transradial catheterization who can provide informed consent and can receive antiplatelet therapy and intravenous anticoagulation are ideal candidates.
Not a fit: Patients who cannot consent, cannot receive antiplatelet or anticoagulant drugs, or who have local access complications such as hematoma or pseudoaneurysm are unlikely to be eligible or benefit.
Why it matters
Potential benefit: If successful, this approach could allow clinicians to avoid unnecessary heparin in some patients while preserving radial artery patency and reducing bleeding risk.
How similar studies have performed: Prior studies have shown routine periprocedural heparin reduces radial artery occlusion, while selective or no-heparin strategies have been less thoroughly tested in randomized comparisons.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient referred for a diagnostic transradial catheterism Exclusion Criteria: * Unable to understand study design or provide informed consent * Unable to receive antiplatelet therapy with aspirina and/or clopidogrel-prasugrel and/or ticagrelor and intravenous anticoagulant derived from heparine or bivalirudine * Local condition such as hematoma or pseudo-aneurims precluding radial or ulnar access. * Presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression (due to colaterals or interouseous artery) precluding the evaluation of patent hemostasis.
Where this trial is running
Québec, Quebec
- Iucpq — Québec, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Michele Jadin
- Email: michele.jadin@criucpq.ulaval.ca
- Phone: 418-656-8711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.